RECLAST
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Aug 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
RECLAST by Novartis is bone. Approved for osteoporosis in postmenopausal women, osteoporosis in postmenopausal women [see clinical studies ()], paget's disease of bone in men and 5 more indications. First approved in 2007.
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RECLAST (zoledronic acid) is an intravenous bisphosphonate that inhibits osteoclast-mediated bone resorption by targeting farnesyl pyrophosphate synthase in osteoclasts. It is indicated for osteoporosis in postmenopausal women and Paget's disease of bone, with a mechanism based on high affinity binding to mineralized bone at sites of elevated turnover.
$0.085BPart D
LOE ApproachingProduct is approaching loss of exclusivity with modest Part D spending of $85K in 2023, indicating a mature, stable market with likely smaller brand team focus on retention and transition planning.
Mechanism of Action
bone. It is an inhibitor of osteoclast-mediated bone resorption. The selective action of bisphosphonates on bone is based on their high affinity for mineralized bone. Intravenously administered zoledronic acid rapidly partitions to bone and localizes preferentially at sites of high bone turnover.…
Worked on RECLAST at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.